Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kaupke, C. J.
Right arrow Articles by Vaziri, N. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kaupke, C. J.
Right arrow Articles by Vaziri, N. D.

Journal of the American Society of Nephrology, Vol 4, 1874-1878, Copyright © 1994 by American Society of Nephrology

REGULAR ARTICLES

Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy

CJ Kaupke, S Kim and ND Vaziri
Department of Medicine, University of California, Irvine, Orange.

Treatment of renal anemia with recombinant human erythropoietin (rEPO) frequently raises arterial blood pressure. The objective of this study was to determine whether this is a direct effect of rEPO or a consequence of the expansion of erythrocyte mass. Twenty-three chronic hemodialysis patients receiving maintenance rEPO therapy who had uncontrolled anemia due to iron deficiency were studied. It was anticipated that repletion of iron stores with iv iron dextran would restore rEPO responsiveness, leading to a gradual rise in hematocrit to the target values (0.30 to 0.33). The effect of the increase in hematocrit on arterial blood pressure could then be dissected from the direct effect of rEPO in patients receiving constant doses of rEPO throughout the study period. To this end, arterial blood pressure, iron indices, hematocrit, and measures of fluid balance were monitored at baseline and for a 10-wk period after iron repletion. In eight patients, the hematocrit transiently rose above 0.33, triggering a reduction in rEPO dosage. In the remaining 15 patients, rEPO dosage was held constant during the study period. In this subgroup, repletion of iron stores led to a rise in hematocrit from 0.25 +/- 0.04 to 0.32 +/- 0.04 (P < 0.001) within 4 wk. Despite the significant rise in hematocrit, both systolic and diastolic blood pressure values remained virtually unchanged. Likewise, body weight and interdialytic fluid gain were unaltered.(ABSTRACT TRUNCATED AT 250 WORDS)


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
N. D. Vaziri and X. J. Zhou
Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease
Nephrol. Dial. Transplant., November 5, 2008; (2008) gfn601v1.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
D. E. Weiner, D. C. Miskulin, K. Seefeld, V. Ladik, P. G. Zager, A. K. Singh, H. K. Johnson, and K. B. Meyer
Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3184 - 3191.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. V. R. Santhanam, L. A. Smith, K. A. Nath, and Z. S. Katusic
In vivo stimulatory effect of erythropoietin on endothelial nitric oxide synthase in cerebral arteries
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H781 - H786.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
B. B. Beleslin-Cokic, V. P. Cokic, X. Yu, B. B. Weksler, A. N. Schechter, and C. T. Noguchi
Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells
Blood, October 1, 2004; 104(7): 2073 - 2080.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. Myssina, S. M. Huber, C. Birka, P. A. Lang, K. S. Lang, B. Friedrich, T. Risler, T. Wieder, and F. Lang
Inhibition of Erythrocyte Cation Channels by Erythropoietin
J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2750 - 2757.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J. Vogel, I. Kiessling, K. Heinicke, T. Stallmach, P. Ossent, O. Vogel, M. Aulmann, T. Frietsch, H. Schmid-Schonbein, W. Kuschinsky, et al.
Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity
Blood, September 15, 2003; 102(6): 2278 - 2284.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
J. W. Fisher
Erythropoietin: Physiology and Pharmacology Update
Experimental Biology and Medicine, January 1, 2003; 228(1): 1 - 14.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
E. BROCHU, S. LACASSE-M, R. LARIVIÈRE, I. KINGMA, J. H. GROSE, and M. LEBEL
Differential Effects of Endothelin-1 Antagonists on Erythropoietin-Induced Hypertension in Renal Failure
J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1440 - 1446.
[Abstract] [Full Text]

Home page
 HypertensionHome page
X. Q. Wang and N. D. Vaziri
Erythropoietin Depresses Nitric Oxide Synthase Expression by Human Endothelial Cells
Hypertension, March 1, 1999; 33(3): 894 - 899.
[Abstract] [Full Text] [PDF]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673